Key Laboratory of Protein Modification and Disease of Liaoning Province, School of Life Science and Biotechnology, Dalian University of Technology, No. 2 Ling Gong Road, Dalian 116024, China.
Department of Gastroenterology and Hepatology, Dalian Municipal Central Hospital Affiliated to Dalian Medical University, No. 826 Xi Nan Road, Dalian 116033, China.
Dis Markers. 2019 Jul 31;2019:5069614. doi: 10.1155/2019/5069614. eCollection 2019.
Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH) and inter-alpha-trypsin inhibitor heavy chain H4 (ITIH) are heavy chains of protein members belonging to the ITI family, which was associated with inflammation and carcinogenesis. However, the diagnostic value of ITIH and ITIH in human colorectal cancer (CRC) remains unknown.
In total, 101 CRC patients and 156 healthy controls were enrolled. The concentrations of ITIH and ITIH proteins in plasma samples of participants were assessed using enzyme-linked immunosorbent assay. ITIH and ITIH expressions in human CRC tissues were additionally assessed via immunohistochemical staining (IHC). Receiver operating characteristic (ROC) was applied to estimate the diagnostic power of the two proteins, and the net reclassification improvement (NRI) was adopted to evaluate the incremental predictive ability of ITIH/ITIH when added to the tissue inhibitor of metalloproteinase-1 (TIMP-1).
The plasma concentration of ITIH in CRC patients (median: 4.370 g/mL; range: 2.152-8.170 g/mL) was significantly lower than that in healthy subjects (median: 4.715 g/mL; range: 2.665-10.257 g/mL; < 0.001), while the ITIH plasma level in subjects with CRC (median: 0.211 g/mL; range: 0.099-0.592 g/mL) was markedly increased relative to that in the control group (median: 0.134 g/mL; range: 0.094-0.460 g/mL, < 0.001). Consistently, IHC score assessment showed a dramatic reduction in ITIH expression and, conversely, upregulation of ITIH in colorectal carcinoma specimens relative to adjacent normal colorectal tissues ( < 0.001 in both cases). The area under the curve (AUC) of the ROC for ITIH (AUC = 0.801, 95% CI: 0.745-0.857) was higher than that for ITIH (AUC = 0.638, 95% CI: 0.571-0.704, both values < 0.001). The AUC of the ROC for combined ITIH and ITIH was even higher than that for carcinoembryonic antigen. NRI results showed that combining ITIH and ITIH with TIMP-1 significantly improved diagnostic accuracy (NRI = 17.12%, = 0.002) for CRC patients compared to TIMP-1 alone.
Circulating ITIH and ITIH levels are associated with carcinogenesis in CRC, supporting their potential diagnostic utility as surrogate biomarkers for colorectal cancer detection.
α-胰蛋白酶抑制剂重链 H3(ITIH)和 α-胰蛋白酶抑制剂重链 H4(ITIH)是 ITI 家族蛋白成员的重链,与炎症和癌变有关。然而,ITIH 和 ITIH 在人结直肠癌(CRC)中的诊断价值尚不清楚。
共纳入 101 例 CRC 患者和 156 例健康对照者。采用酶联免疫吸附试验(ELISA)检测参与者血浆样本中 ITIH 和 ITIH 蛋白的浓度。此外,还通过免疫组织化学染色(IHC)评估 ITIH 在人 CRC 组织中的表达。应用受试者工作特征(ROC)曲线估计两种蛋白的诊断效能,并采用净重新分类改善(NRI)评估 ITIH/ITIH 加入基质金属蛋白酶抑制剂-1(TIMP-1)后对预测能力的增量。
CRC 患者的 ITIH 血浆浓度(中位数:4.370 g/mL;范围:2.152-8.170 g/mL)明显低于健康对照组(中位数:4.715 g/mL;范围:2.665-10.257 g/mL; < 0.001),而 CRC 患者的 ITIH 血浆水平(中位数:0.211 g/mL;范围:0.099-0.592 g/mL)明显高于对照组(中位数:0.134 g/mL;范围:0.094-0.460 g/mL, < 0.001)。免疫组化评分评估显示,ITIH 表达明显降低,而相反,结直肠癌标本中 ITIH 的表达上调,与相邻正常结直肠组织相比(两种情况均 < 0.001)。ITIH 的 ROC 曲线下面积(AUC)为 0.801(95%CI:0.745-0.857),高于 ITIH(AUC = 0.638,95%CI:0.571-0.704,均 < 0.001)。联合 ITIH 和 ITIH 的 ROC 的 AUC 甚至高于癌胚抗原。NRI 结果表明,与单独使用 TIMP-1 相比,联合 ITIH 和 ITIH 可显著提高 CRC 患者的诊断准确性(NRI = 17.12%, = 0.002)。
循环 ITIH 和 ITIH 水平与 CRC 中的癌变有关,支持它们作为结直肠癌检测的替代生物标志物的潜在诊断价值。